Valeant Pharmaceuticals To Syndicate Incremental Loans
MONTREAL, Sept. 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced plans to syndicate an additional $1,000,000,000 of incremental term B loans under its existing senior secured credit facilities. The incremental term B loans will be used to provide a portion of the financing for Valeant's anticipated acquisition of all of the outstanding common stock of Medicis Pharmaceutical Corporation (NYSE: MRX). The incremental term B loans will have a seven year term and are expected to have terms that are substantially similar to the Company's existing Term Loan B facility. The incremental term B loans are expected to close in the first half of 2013, concurrent with the closing of the transaction. The Company also intends, subject to market and other conditions, to raise approximately $500,000,000 of unsecured debt for general corporate purposes, including acquisitions.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
This press release may contain forward-looking statements. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements which include statements regarding our plans to syndicate incremental term loans and the proposed terms thereof and our expectation as to when and if the incremental term loan facility will close, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and risks and uncertainties as detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
Laurie W. Little
SOURCE Valeant Pharmaceuticals International, Inc.
More by this Source
Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
Dec 16, 2013, 08:00 ET
Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance
Dec 13, 2013, 18:35 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.